Although the screening test to detect the most common cause of Spinal Muscular Atrophy (SMA) (homozygous deletion/disruption of SMN1) has been available in South Africa for more than 2 decades, only isolated cases are able to access gene therapies for SMA which are available in resource-rich countries. This evidence concerns the gene SMN1 and spinal muscular atrophy.